TORONTO, Dec. 8 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it will report its fourth quarter and full year fiscal 2009 financial results on Friday, December 18, 2009.
In conjunction with this announcement, Patheon will host a conference call with financial analysts on Friday, December 18, 2009 at 10:00 a.m. (EST) to discuss its fiscal 2009 financial results. The financial results news release will be issued at approximately 7:00 a.m. (EST) on Friday, December 18, 2009.
Interested parties are invited to access the live call, via telephone, in listen-only mode, toll free at 1-888-231-8191 (U.S., including Puerto Rico) and 1-647-427-7451 (Canada and International). Listeners are encouraged to dial in five to fifteen minutes in advance to avoid delays. A live audio will also be available via the web at www.patheon.com. (Please note that Windows Media Player or RealPlayer is required.)
A telephone replay of the conference call will be available between Friday, December 18, 2009 and Friday, December 25, 2009 by calling 1-800-642-1687 (toll free) or 1-403-451-9481,and by entering identification number 45831351, followed by the number key. The conference call will also be archived at www.patheon.com for three months.
Patheon Inc. (TSX: PTI) is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.
Patheon's integrated development and manufacturing network of 11 facilities, and eight development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.
SOURCE Patheon Inc
For further information: For further information: Contacts: Mr. Wes Wheeler, President & Chief Executive Officer, Tel: (919) 226-3200, Email: email@example.com; Mr. Eric Evans, Chief Financial Officer, Tel: (919) 226-3204, Email: firstname.lastname@example.org; Ms. Wendy Wilson, Investor Relations, Tel: (919) 226-3313, Email: email@example.com